The company has also made strategic moves to strengthen its pipeline and market position. Madrigal entered a global licensing agreement with CSPC Pharma to incorporate an oral GLP-1 into its offerings. Additionally, a new Orange Book listed patent for Rezdiffra extends its protection until 2045. The launch of Rezdiffra in Germany following European Commission approval further expands its market reach. Financially, Madrigal has a negative P/E ratio of -35.13, reflecting its current lack of profitability. How ...